ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.110,38
-0,16%
S&P 500
5.667,20
0,64%
US Dollar vs BRL
5,4259
-0,41%
Bitcoin
65.284,21
0,64%
Brent Oil
83,315
-1,22%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Champions Oncology Inc (CSBR)

  7. Champions Oncology Inc (CSBR) Notícias

CSBR

Champions Oncology (CSBR)

Champions Oncology Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CSBR
DataHoraFonteTítuloCódigoCompanhia
11/03/201611:00PR Newswire (US)Champions To Present at the 28th Annual ROTH Capital Conference on March 16, 2016NASDAQ:CSBRChampions Oncology Inc
10/03/201612:00PR Newswire (US)Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2016NASDAQ:CSBRChampions Oncology Inc
07/03/201619:15Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CSBRChampions Oncology Inc
21/01/201614:00PR Newswire (US)Champions Oncology Announces Initiation of Prospective Correlative Trial in SarcomaNASDAQ:CSBRChampions Oncology Inc
15/12/201520:23Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CSBRChampions Oncology Inc
14/12/201519:50PR Newswire (US)Champions Oncology Reports Results for the Second Quarter Ended October 31, 2015NASDAQ:CSBRChampions Oncology Inc
14/12/201519:01PR Newswire (US)Champions Oncology Leading Paradigm Shift to Incorporation of PDX Models into Clinical Trial StrategyNASDAQ:CSBRChampions Oncology Inc
10/12/201513:45PR Newswire (US)Champions Oncology to Announce Second Quarter Financial Results on Monday, December 14, 2015NASDAQ:CSBRChampions Oncology Inc
30/11/201514:51PR Newswire (US)Champions Oncology to Present at LD MICRO Investor ConferenceNASDAQ:CSBRChampions Oncology Inc
23/11/201517:18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CSBRChampions Oncology Inc
15/10/201507:03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:CSBRChampions Oncology Inc
14/10/201507:01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CSBRChampions Oncology Inc
25/09/201515:41Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:CSBRChampions Oncology Inc
10/09/201517:05PR Newswire (US)Champions Oncology Reports Results for the First Quarter Ended July 31, 2015NASDAQ:CSBRChampions Oncology Inc
08/09/201511:30PR Newswire (US)Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2015NASDAQ:CSBRChampions Oncology Inc
01/09/201518:10Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:CSBRChampions Oncology Inc
31/08/201514:54Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CSBRChampions Oncology Inc
21/08/201510:38PR Newswire (US)Champions Oncology Announces Uplisting to NASDAQNASDAQ:CSBRChampions Oncology Inc
15/12/200920:00PR Newswire (US)Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial ResultsNASDAQ:CSBR
18/11/200911:00PR Newswire (US)Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the RepurposingNASDAQ:CSBR
12/11/200911:52PR Newswire (US)Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to GuNASDAQ:CSBR
27/10/200910:00PR Newswire (US)Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment ofNASDAQ:CSBR
26/10/200910:52PR Newswire (US)Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)NASDAQ:CSBR
13/10/200909:52PR Newswire (US)U.S. Patent Issued for Champions Biotechnology's Lead Oncology DrugNASDAQ:CSBR
14/09/200921:44PR Newswire (US)Champions Biotechnology Reports Fiscal 2010 First Quarter Financial ResultsNASDAQ:CSBR
10/09/200909:23PR Newswire (US)Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration AgreementNASDAQ:CSBR
09/09/200911:11PR Newswire (US)Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare ConferenceNASDAQ:CSBR
01/09/200909:55PR Newswire (US)Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech LeaderNASDAQ:CSBR
27/08/200917:26PR Newswire (US)Champions Biotechnology Reports Fiscal 2009 Full-Year Financial ResultsNASDAQ:CSBR
16/07/200909:22PR Newswire (US)Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) TeNASDAQ:CSBR
 Apresentando as notícias mais relevantes sobre:NASDAQ:CSBR

Seu Histórico Recente

BOV
HAGA3
HAGA ON
BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
AZEV4
AZEVEDO PN
BOV
GFSA3
GAFISA ON
BOV
AMER3
Americanas ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
COGN3
COGNA ON
BOV
NGRD3
Neogrid Participacoes ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
VVEO3
CM Hospitalar ON
BOV
AMAR3
LOJAS MARISA ON
BOV
JFEN3
JOAO FORTES ON
BOV
GOLL4
GOL PN
BOV
HBOR3
HELBOR ON
BOV
AGXY3
Agrogalaxy Participacoes ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados